Patents by Inventor Pedro Lopez Saura

Pedro Lopez Saura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Stabilized pharmaceutical formulations that contain the interferons gammas and alpha in synergistic proportions
    Patent number: 8535657
    Abstract: The present invention is related to stable pharmaceutical formulations to be applied by parenteral (liquids or freeze-dried), or topic way (gel, unguent or cream) that contain different quantities of the recombinant interferons gamma and alpha in synergistic proportions for the treatment of pathological events that contemplate the malignant or benign not-physiological growth of cells in tissue or organs.
    Type: Grant
    Filed: October 27, 2006
    Date of Patent: September 17, 2013
    Assignee: Centro de Ingenieria Genetica y Biotecnologia
    Inventors: Iraldo Bello Rivero, Pedro Lopez Saura, Yanelda Garcia Vega, Hector Santana Milian, Ana Aguilera Barreto, Rolando Paez Meireles, Lorenzo Anasagasti Angulo
  • STABILIZED PHARMACEUTICAL FORMULATIONS THAT CONTAIN THE INTERFERONS GAMMA AND ALPHA IN SYNERGISTIC PROPORTIONS
    Publication number: 20090304628
    Abstract: The present invention is related to stable pharmaceutical formulations to be applied by parenteral (liquids or freeze-dried), or topic way (gel, unguent or cream) that contain different quantities of the recombinant interferons gamma and alpha in synergistic proportions for the treatment of pathological events that contemplate the malignant or benign not-physiological growth of cells in tissue or organs.
    Type: Application
    Filed: October 27, 2006
    Publication date: December 10, 2009
    Inventors: Iraldo Bello Rivero, Pedro López Saura, Yanelda Garcia Vega, Héctor Santana Milian, Ana Aguilera Barreto, Rolando Pâez Meireles, Lorenzo Anasagasti Angulo
  • Chimeric antagonist anth1
    Patent number: 7429384
    Abstract: A recombinant chimeric antagonist formed by a 60 amino acid fragment of the N-terminal region of human interleukin 2 (IL-2) fused to the N-terminal of the extracellular region of the alpha subunit of the gamma IFN (IFN ?) receptor. In vitro this protein has a T cell growth stimulating activity, it inhibits the growth stimulating activity of IL-2 in T cells, it inhibits the induction of HLA-DR by IFN ? and it inhibits the antiproliferative activity of ? IFN. This invention can be applied in the field of medicine for the treatment of several pathologies such as autoimmune diseases, graft rejections, chronic inflammations, sepsis, ischemia and reperfusion syndrome and atherosclerosis.
    Type: Grant
    Filed: May 8, 2003
    Date of Patent: September 30, 2008
    Assignee: Centro de Ingenieria Genetica y Biotecnologia
    Inventors: Iraldo Bello Rivero, Yeny Torres Ruiz, Elizabeth Blanco Garcés, Giselle Pentón Roll, Pedro López Saura